Niagen Bioscience Inc
HealthcareNASDAQ:NAGE · NASDAQ Capital Market
+$0.02 today
Vol 0.47M · Avg 0.97M
Intrinsic Value
NAGE Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Intrinsic Value
System DCF · consensus of 4 models
Sign in to unlock intrinsic value
Free accounts get 5 valuations per week. Upgrade for more.
Monitor NAGE
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price Alerts
Get notified when NAGE drops below a target
Sign in to activate price alerts · unlock IV-based targets
Valuation History
Is NAGE cheaper or more expensive than usual?
Review how the market has valued Niagen Bioscience Inc over time before deciding whether today’s discount or premium is unusual.
Price History
Dividend-adjusted closing price
Change
-74.69%
Period High
$14.41
Period Low
$3.37
Latest
$3.45
Analyst Targets
See where analysts expect NAGE to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$3.45
Low Target
$10.00
Avg Target
$10.50
High Target
$11.00
Upside (Avg)
+204.35%
Alternatives to NAGE
Compare Niagen Bioscience Inc with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
$747.81M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Keros Therapeutics, Inc.
NASDAQ:KROS
$324.78M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Fundamental Analysis
Capture the investment case and test company quality
Write down the key idea, risks, and what would change your mind. Then review growth, profitability, returns, owner payouts, and insider activity.
My Notes
Journal entries for NAGE
Sign in to keep notes
Track your buy/sell/hold decisions for every stock in your personal journal.
Quality Snapshot
Start with the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | +15.5% | +16.8% |
Equity | +15.4% | +12.0% | -1.5% | +75.6% |
Cash | N/A | N/A | +120.2% | +40.0% |
ROIC | -88.1% | -84.7% | -91.6% | -66.4% |
Analysis
Latest growth is strongest in Equity at +75.6% and weakest in ROIC at -66.4%. Three-year average ROIC is -91.6%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +15.5% | +20.6% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +15.5% over three years. Forward estimates point to Revenue at +20.6% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$130.4M of revenue converted into $18.6M of net income for the selected period. Gross margin is 64.3% and net margin is 14.3%, showing how much revenue survives after costs and taxes. EPS is $0.22, tying the income statement back to per-share earnings.
Capital Efficiency
Measure how well Niagen Bioscience Inc turns capital into returns
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
22.7%
avg -56.7%
ROIC
15.6%
avg -45.9%
ROA
16.3%
avg -28.7%
Analysis
ROE is currently the strongest return metric at 22.7% versus its period average of -56.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Owner Returns
Review how cash comes back to shareholders
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
0.94%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
0.95%
Analysis
Total TTM shareholder yield is 0.95% including 0.00% from debt paydown. The largest current contributor is buybacks at 0.94%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Dividend Record
Check payout durability before counting on yield
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.09%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Company Overview
Understand how Niagen Bioscience Inc makes money
Finish by grounding the numbers in the company profile, leadership, balance sheet, and free cash flow.
Key Information
Leadership
Put the business in management context
Company facts explain what Niagen Bioscience Inc does; leadership context helps you judge who is responsible for capital allocation and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert N. Fried | Chief Executive Officer & Director | $1.21M | — | 66 | $1.06M | 1.33% |
Ozan Pamir | Chief Financial Officer & Principal Accounting Officer | $648,236.00 | — | 34 | $62,131.00 | 0.08% |
Carlos Lopez | Senior Vice President & General Counsel | $480,029.00 | — | 45 | $41,420.00 | 0.05% |
James Lee | Controller | $286,491.00 | — | 50 | — | — |
Frank Louis Jaksch Jr. | Co-Founder & Chairman | $70,000.00 | — | 58 | $20,000.00 | 0.03% |
Lauren Rittman-Borzansky | Assistant Controller | — | — | — | — | — |
Michiko Kelley | Chief Marketing Officer | — | — | — | — | — |
Wesley Yu | Vice President of Finance | — | — | — | $20,000.00 | 0.03% |
Andrew Shao | Senior Vice President of Global Regulatory & Scientific Affairs | — | — | — | — | — |
Kendall Knysch | Head of Media Relations & Partnerships | — | — | — | — | — |
Chu Yan | Managing Director of Asia Pacific | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$45,616.43
Sells
0
$0.00
Net Sentiment
+$45,616.43
Net buying
Most Active
Pamir Ozan
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | Pamir Ozan Direct | Buy | 4.5K | $6.81 | $30,406.39 | |
| Nov 14, 2025 | Pamir Ozan Indirect | Buy | 2.2K | $6.85 | $15,210.03 |
Analysis
Insiders reported 2 buys worth $45,616.43 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $45,616.43. Pamir Ozan was the most active insider with 2 transactions.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $66.5M |
| Receivables | $13.1M |
| Inventory | $24.0M |
| Other Current | $1.5M |
| Total Current Assets | $105.1M |
| PP&E (Net) | $3.3M |
| Intangible Assets | $5.5M |
| Other Non-current | $406.0K |
| Total Non-current Assets | $9.2M |
| Total Assets | $114.3M |
Analysis
Selected assets total $114.3M for Latest. The largest visible component is Cash & Equivalents at $66.5M, about 58.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Finish by testing whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Explore More
Continue the stock analysis
Jump to another research area for this company.